الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 125 |  |  |
| | | from | 125 | | |
Abstract
Coronavirus disease 2019 (COVID-19) is an infectious sickness caused by the SARS-CoV-2 coronavirus that produces severe acute respiratory syndrome. Authorities detected the first documented case in Wuhan, China, in December 2019. Since then, the sickness has spread worldwide, resulting in a pandemic that is currently ongoing.
Complications of pediatric COVID-19 can affect a range of organs and systems, including the cardiovascular system.
In actuality, 35-100% of patients are concerned about the possibility of myocarditis, heart failure, cardiogenic shock, and pericardial effusion. This emphasizes the importance of doing imaging examinations on a frequent basis. Patients with MIS-C experienced cardiac problems.
The virus directly damages myocardial cells by binding to the ACE2 receptors on these cells, causing direct cardiac injury. It is widely accepted that ACE2 and angiotensin have beneficial effects on the heart. Their combination inhibits oxidative stress and cardiac remodeling while also causing coronary vasorelaxation.
Inflammatory markers are linked to abnormal electrocardiograms and cardiac injury.
Increases in cardiac biomarkers are accompanied by an increase in inflammatory markers, which is connected to heart damage. As time passes, significant clinical symptoms emerge, as do greater rates of morbidity and mortality.
The findings of a retrospective cohort research indicated the potential relevance of troponin I levels in predicting cardiac damage in children with COVID-19 and the need for additional testing by a pediatric cardiologist.
The substantial systemic inflammation reported in COVID-19 may trigger cardiovascular damage. In vitro studies demonstrated left ventricular systolic dysfunction and reduced contractility.